Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

TechTour Europe Future 2022 Award Winner

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022

EIT Health Catapult Biotech pitching competition Finalist StemSight

Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.

22/03/2024

StemSight moves to second phase of EIC Accelerator

As an innovative technology company focused on creating lasting benefits to the European health ecosystem, StemSight is a prime candidate for EU's EIC Accelerator funding. This highly competitive funding scheme requires two application phases, and a final interview. We are glad to announce that we have received very positive evaluation from the four independent evaluators on our first phase application and are eager to move to the next step!

13/03/2024

Laura Koivusalo finalist for Young Researcher Entrepreneur of the Year

Our CEO Laura has been nominated and selected as one of the three finalists for KAUTE Foundation's Young Research Entrepreneur of the Year award. This is already her second nomination for the award.

19/03/2024

Laura Koivusalo speaks at Advanced Therapies in London

Our CEO Laura attends the Advanced Therapies event in London on March 19-20. Laura joins other prominent Cell and Gene Therapy leaders in an expert panel on Autologous vs. Allogeneic approaches in cell therapy.

17/02/2024

StemSight prominently featured in Yle news piece

The premier news outlet in Finland, Yle, did an extensive news feature article about StemSight, including a video filmed at our research labs. The video was also aired in local news.

MORE NEWS